STOCK TITAN

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals submits IND application to FDA for NRX-101 to treat Chronic Pain
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals announces multiple near-term data catalysts and collaborations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
Rhea-AI Summary
NRx Pharmaceuticals to release Q2 2023 financial results on August 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
conferences earnings
-
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) has licensed US Patent 8,653,120 for the use of D-Cycloserine to treat Chronic Pain. This agreement includes commitments to pay milestones and royalties as development progresses. Dr. Vania Apkarian, a renowned pain and D-Cycloserine researcher, has joined NRx's Scientific Advisory Board. NRx has also focused on developing NRX-101 to treat Chronic Pain, with potential to decrease chronic and neuropathic pain and reduce opioid craving. The company has conducted non-clinical and early clinical studies showing NRX-101's non-neurotoxic and non-addictive properties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals to present company overview at H.C. Wainwright Neuropsychiatry Virtual Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences
Rhea-AI Summary
NRx Pharmaceuticals has closed its registered direct offering, raising approximately $6.28 million. The company intends to use the net proceeds for working capital and general corporate purposes, as well as research into the use of NRX-101 for the treatment of PTSD and Chronic Pain. The offering was made under a shelf registration statement and the warrants offered have not been registered under the Securities Act.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
-
Rhea-AI Summary
NRx Pharmaceuticals has entered into definitive agreements for the purchase and sale of 9,670,002 shares of common stock in a registered direct offering. The gross proceeds from the offering are expected to be approximately $6.28 million. The company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.71%
Tags
-
Rhea-AI Summary
NRx Pharmaceuticals, Inc. will host a corporate and strategic update conference call on June 5, 2023 at 8:30 a.m. EDT. The conference call will be available via webcast on the Company's website and a live archive will be available for 30 days. Participants can also join the call via telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.92%
Tags
conferences
Rhea-AI Summary
NRx Pharmaceuticals announces financial results for Q1 2023 and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach